https://www.optimumcomms.com/wp-content/uploads/2023/06/NovoFund_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-01-15 09:08:122026-01-15 09:09:38Novo Nordisk Foundation grants DKK 5.5 billion to elevate innovation in Denmark and Europe
https://www.optimumcomms.com/wp-content/uploads/2023/06/NovoFund_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-01-15 09:08:122026-01-15 09:09:38Novo Nordisk Foundation grants DKK 5.5 billion to elevate innovation in Denmark and Europe
https://www.optimumcomms.com/wp-content/uploads/2025/09/AMS.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-01-15 07:07:382026-01-15 17:09:37AMS: Full Year 2025 Trading Update
https://www.optimumcomms.com/wp-content/uploads/2026/01/Kainova_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-01-12 08:53:132026-01-12 08:53:13Domain Therapeutics Rebrands as Kainova Therapeutics Advancing Its Clinical Pipeline of GPCR-Modulating Therapies
https://www.optimumcomms.com/wp-content/uploads/2026/01/NanoSyrinx_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-01-08 08:46:532026-01-08 08:46:53Seasoned biotherapeutics leader Thomas J. Farrell joins NanoSyrinx as CEO to advance Nanosyringe-enabled intracellular medicines
https://www.optimumcomms.com/wp-content/uploads/2023/02/StormTx_Logo_300-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-01-08 08:41:162026-01-08 08:41:16STORM Therapeutics and AlidaBio Announce Strategic Collaboration to Accelerate Development of Cancer Therapies Targeting RNA Modifications
https://www.optimumcomms.com/wp-content/uploads/2023/02/ViCentra_Logo_300x180px-3.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-01-08 08:00:562026-01-08 08:01:42ViCentra Expands Financing to $98 Million to Accelerate European Commercialization and Ready Next Generation Kaleido Insulin Patch Pump System for U.S. Access
https://www.optimumcomms.com/wp-content/uploads/2026/01/Tecregen_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-01-08 08:00:002026-01-08 12:48:45TECregen Raises CHF 10 Million in Seed Financing and Appoints Dr. Bo Rode Hansen as Chairman
https://www.optimumcomms.com/wp-content/uploads/2023/06/Synaffix_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-01-07 09:22:412026-01-07 15:55:19Lonza’s Synaffix and Sidewinder Therapeutics Announce Multi-Target License Agreement to Advance Development of Next‑Generation Bispecific ADCs
https://www.optimumcomms.com/wp-content/uploads/2026/01/Nucleome_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-01-07 09:03:292026-01-07 09:03:29Nucleome Therapeutics nominates first preclinical development candidate
https://www.optimumcomms.com/wp-content/uploads/2025/04/AstronauTx_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-01-07 08:33:422026-01-07 08:33:42AstronauTx appoints experienced biotech executive Adam Rosenberg as Chair of the Board
https://www.optimumcomms.com/wp-content/uploads/2026/01/Acension_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-01-06 10:56:522026-01-06 10:56:52Acesion Pharma starts Phase 2 trial of AP31969 in patients with atrial fibrillation
https://www.optimumcomms.com/wp-content/uploads/2024/10/Loqus23_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-01-06 08:37:282026-01-06 08:37:28LoQus23 Therapeutics nominates LQT-23 as first-in-class, oral drug candidate for Huntington’s Disease
https://www.optimumcomms.com/wp-content/uploads/2025/12/Numares_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-12-17 10:05:592025-12-17 10:05:59numares Health enters ASEAN region with regulatory approval in Malaysia and first contract win for AXINON ® LDLp Test System
https://www.optimumcomms.com/wp-content/uploads/2025/08/Leucid_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-12-15 13:36:192025-12-15 13:36:19Leucid Bio and Syenex Announce Strategic Collaboration for In Vivo CAR-T Cell Engineering
https://www.optimumcomms.com/wp-content/uploads/2024/04/Fibrocor_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-12-09 09:02:532025-12-09 09:04:02Fibrocor Therapeutics appoints world-leading nephrologists to Clinical Advisory Board with a focus on its lead indication Alport Syndrome
https://www.optimumcomms.com/wp-content/uploads/2023/12/Poolbeg_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-12-08 07:14:122025-12-08 07:14:12Poolbeg Pharma plc – POLB 001 trial to feature in groundbreaking cancer immunotherapy-induced CRS research programmeWe’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
